Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients

Pharmacogenomics Journal

Volumn 9, Issue 3, 2009, Pages 168-174

  Zai, C C ^a   Tiwari, A K ^a   Basile, V ^a   De Luca, V ^a   Muller D J ^a   King, N ^a   Voineskos, A N ^a   Remington, G ^a   Meltzer, H Y ^b   Lieberman, J A ^c   Potkin, S G ^d   Kennedy, J L ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b VANDERBILT UNIVERSITY   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR;

ADULT; ARTICLE; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HAPLOTYPE; HOMOZYGOSITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA; VARIABLE NUMBER OF TANDEM REPEAT;

ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; EXONS; GENE DOSAGE; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D4; SCHIZOPHRENIA; TANDEM REPEAT SEQUENCES;

EID: 67349139913     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.2     Document Type: Article

References (73)

1. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005; 50: 703-714.
2. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Disord 2006; 21: 589-598.
3. Marsalek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000; 33(S1): 14-33.
4. Gerlach J. Improving outcome in schizophrenia: The potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14 47-57.
5. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
6. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087.
7. Correll CU, Leucht S, Kane JM. Lower risk of tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-425.
8. Kane JM. Tardive dyskinesia circa 2006. Am J Psychiatry 2006; 163: 1316-1318.
9. Remington G. Tardive dyskineisa: Eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007; 20: 130-137.
10. Correll CU, Schank EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151-156.
11. Woerner MG, Alvir JMJ, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. Am J Psychiatry 1998; 155: 1521-1528.
12. Kane JM, Woerner M, Lieberman J. Epidemiological aspects of tardive dyskinesia. L'Encephale 1988; 14S: 191-194.
13. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50: 723-733.
14. Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007a; 10 639-651.
15. Smith JM, Dunn DD. Sex differences in the prevalence of severe tardive dyskinesia. Am J Psychiatry 1979; 136: 1080-1082.
16. Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999; 7: 70-76.
17. Menza MA, Grossman N, Van Horn M, Cody R, Forman N. Smoking and movement disorders in psychiatric patients. Biol Psychiatry 1991; 30: 109-115.
18. Bailey LG, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: A retrospective analysis of 1,027 patients. Psychopharmacol Bull 1997; 33: 177-181.
19. Dixon L, Weiden PJ, Haas G, Sweeney J, Frances AJ. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992; 33: 121-122.
20. Stoessl AJ. Effects of ethanol in a putative rodent model of tardive dyskinesia. Pharmacol Biochem Behav 1996; 54: 541-546.
21. Müller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T et al Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375-379.
22. Tarsy D, Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1977; 12: 431-450.
23. Klawans HL, Goetz CG, Perlik S. Tardive dyskinesia: Review and update. Am J Psychiatry 1980; 137: 900-908.
24. Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatrica Scand 1988; 77: 369-378.
25. Abilio VC, Vera Jr JAR, Ferreira LSM, Duarte CRM, Martins CR, Torres-Leite D et al. Effects of melatonin on behavioral dopaminergic supersensitivity. Life Sciences 2003; 72: 3003-3015.
26. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research. Mol Psychiatry 2007; 12: 707-747.
27. Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain gaba synthesis. Nature 1984; 309: 347-349.
28. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacol 1994; 11: 245-256.
29. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993; 54 327-330.
30. Beasley Jr CM, Dellva M, Tamura RN, Morgenstern H, Glazer WM, Ferguson K et al. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23-30.
31. Jeste DV, Rockwell E, Harris MG, Lohr JB, Lacro J. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatric Psychiatry 1999a; 7: 70-76.
32. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatric Soc 1999b; 47: 716-719.
33. Johansson P, Casey DE, Gunne LM. Dose-dependent increases in rat spontaneous chewing rates during long-term administration of haloperidol but not clozapine. Psychopharmacol Bull 1986; 22: 1017-1019.
34. Gao X, Sakai K, Tamminga CA. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Neuropsychopharmacol 1998; 19: 428-433.
35. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1159-1172.
36. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998; 3: 123-134.
37. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptos explain the action of atypical antipsychotics: A new hypothesis. Am J Psychiatry 2001; 158: 36-369.
38. Bassitt DP, Louzã Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1998; 248: 209-211.
39. Zai CC, De Luca V, Hwang RW, Voineskos AN, Müller DJ, Remington G et al. Meta-analysis of two Dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry 2007b; 12: 794-795.
40. Rivera A, Cuéllar B, Girón FJ, Grandy DK, de la Calle A, Moratalla R. Dopamine D4 receptors are heterogeneously distributed in the striosomes/matrix compartments of the striatum. J Neurochem 2002; 80: 219-229.
41. Zhang K, Davids E, Tarazi FI, Baldessarini RJ. Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions. Psychopharmacology (Berl) 2002; 161: 100-106.
42. Zhang K, Tarazi FI, Baldessarini RJ. Role of dopamine D(4) receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions in rats. Neuropsychopharmacology 2001; 25: 624-632.
43. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-614.
44. Schoots O, Van Tol HH. The human dopamine D4 receptor repeat sequences modulate expression. Pharmacogenomics J 2003; 3: 343-348.
45. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995; 65: 1157-1165.
46. Segman RH, Goltser T, Heresco-Levy U, Finkel B, Shalem R, Schlafman M et al. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 2003; 3: 277-283.
47. Lattuada E, Cavallaro R, Serretti A, Lorenzi C, Smeraldi E. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: An association study with repeated assessment. Int J Neuropsychopharmacol 2004; 7: 489-493.
48. Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006; 16: 111-117.
49. Lee HJ, Kang SG, Choi JE, Paik JW, Kim YK, Kim SH et al. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. Neuropsychobiology 2007; 55: 47-51.
50. Müller DJ, Shinkai T, De Luca V, Kennedy JL. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004; 4: 77-87.
51. Shale H, Tanner C. Pharmacological options for the management of dyskinesia. Drugs 1996; 52: 849-860.
52. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997; 23: 583-609.
53. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61(Suppl 3): 16-21.
54. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: Design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19: 149-150.
55. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R et al Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene ser9gly polymorphism. Neuropsychopharmacol 2002; 27: 105-119.
56. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: A meta-analysis. Schizophr Res 2006; 83: 185-192.
57. Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JPA. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: A meta-analysis. Pharmacogenet Genomics 2005; 15: 151-158.
58. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: A meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13: 544-556.
59. Lerer B, Segman RH, Tan E-C, Basile VS, Cavallaro R, Aschauer HN et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005; 8: 411-425.
60. Gunes A, Dahl ML, Spina E, Scordo MG. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 2008; 64: 477-482.
61. Thelma BK, Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes. Schizophr Res 2007; 92 278-279.
62. Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008; 18: 317-323.
63. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, (4th edn). American Psychiatric Association: Washington, DC.
64. Guy W (1976) Abnormal involuntary movement scale. In: ECDEU Assessment Manual for Psychopharmacology (Revised edn). Department of Health, Education and Welfare: Washington, DC pp 534-537.
65. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487.
66. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacol 1999; 21: 17-27.
67. Lahiri DK, Nurnburger Jr JI. A rapid non-enzymatic method for the preparation of HMV DNA from blood for RFLP analysis. Nucleic Acids Res 1991; 19: 5444.
68. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21 263-265.
69. Hodgkinson CA, Xu K, Yuan Q, Shen P-H, Heinz E, Lobos EA et al. Addictions biology: Haplotype based analysis for 130 candidate genes on a single array. Alcohol Alcohol 2008; 43: 505-515.
70. Statistical Package for the Social Sciences (2000) SPSS for Windows Rel. 10.0.7. SPSS Inc.: Chicago.
71. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25: 115-121.
72. Hwang R, Shinkai T, Deluca V, Mueller DJ, Ni X, Macciardi F et al. Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractoryintolerant populations. Psychopharmacol (Berl) 2005; 181: 179-187.
73. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59 97-105.